The FDA needs new authority over drug compounders to prevent disasters such as the meningitis outbreak tied to tainted custom-made drugs from the New England Compounding Center, FDA Commissioner Dr. Margaret Hamburg told members of a House Energy and Commerce subcommittee. The present system "hampered our ability to act to protect patients and prevent, rather than just react to, safety concerns," Hamburg said. Several lawmakers sharply criticized the FDA, and committee Chairman Fred Upton, R-Mich., faulted the agency for not following up after finding problems years ago.
Criticized at hearing, FDA calls for new authority
SmartBrief Job Listings for Health Care
|President/Chief Executive Officer||
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Director, Payer Marketing||
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Chief Medical Officer, Texas Children's Health Plan||
Cejka Executive Search for Texas Childre's Health Plan